- Report
- February 2024
- 70 Pages
South Africa
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Spain
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Iran
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Russia
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Australia
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
China
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Japan
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
Japan
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4514EUR$4,750USD£3,841GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4514EUR$4,750USD£3,841GBP
- Report
- August 2023
- 70 Pages
Spain
From €4514EUR$4,750USD£3,841GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4514EUR$4,750USD£3,841GBP
- Report
- October 2022
- 176 Pages
Global
From €4514EUR$4,750USD£3,841GBP
- Report
- October 2022
- 70 Pages
Africa
From €4514EUR$4,750USD£3,841GBP
- Report
- October 2019
- 125 Pages
Canada
From €4514EUR$4,750USD£3,841GBP
- Report
- March 2019
- 160 Pages
Middle East, Africa
From €4514EUR$4,750USD£3,841GBP
- Report
- March 2019
- 90 Pages
Europe
From €4514EUR$4,750USD£3,841GBP
Apidra is a brand of insulin glulisine, a fast-acting insulin analog used to treat diabetes mellitus. It is used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. Apidra is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, metabolism, and other body functions.
The Endocrine and Metabolic Disorders Drugs market is a rapidly growing market, driven by the increasing prevalence of diabetes and other endocrine and metabolic disorders. The market is expected to continue to grow in the coming years, driven by the increasing demand for new and improved treatments.
Some of the major companies in the Apidra market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and AstraZeneca. Show Less Read more